查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837193

病毒惰性市場按產品、方法、應用和最終用戶分類－2025-2032年全球預測

Viral Inactivation Market by Product, Method, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，病毒惰性市場規模將達到 34.3 億美元，複合年成長率為 15.04%。

關鍵市場統計數據
基準年 2024 11.1億美元
預計年份：2025年 12.8億美元
預測年份 2032 34.3億美元
複合年成長率 (%) 15.04%

揭示病毒惰性的策略和科學背景，重點是闡述跨部門促進因素以及為何綜合解決方案對營運韌性至關重要

病毒惰性領域已發展成為一個技術高度複雜、跨學科的領域，它融合了法律規範和營運要求，旨在保護公眾健康和保障商業連續性。本導言探討了影響現代決策的關鍵主題：化學、物理和熱力方法之間的技術融合；各類產品監管力度的加強；以及從研發到部署的全程驗證的日益重視。闡明這些背景有助於相關人員更好地理解，耗材和設備的創新是如何受到空氣、水、食品和製藥系統實際需求的驅動。

此外，本導言重點闡述了為何綜合方法正日益受到支持。對於希望在各種環境條件下獲得可重複結果的機構而言，將消毒劑和化學試劑套件等耗材與專用設備相結合的多學科策略至關重要。同時，法規遵循和操作人員安全的考量正推動產品設計朝向降低毒性、增強可追溯性和簡化通訊協定發展。因此，本導言將病毒惰性定位為一項策略能力，它不僅關乎實驗室層面，更關乎整個供應鏈和關鍵服務的韌性。

新興技術、監管重點和業務需求如何融合，從而重塑通訊協定並促進病毒惰性方法的整合

病毒惰性領域正經歷一場變革，這主要得益於技術進步和相關人員不斷變化的需求。新型設備和自動化技術提高了處理效率和一致性，而化學配方和紫外線光源的創新則改善了頻譜覆蓋範圍和材料相容性。因此，從業人員正逐漸從依賴單一方法轉向結合化學、熱學和物理方法的混合通訊協定，以實現對各種基質的高效去活化。

監管和社會壓力也在改變產品的採用模式。除了遵守既定標準外，企業現在還面臨永續性、員工安全和可驗證可追溯性的要求。這些趨勢促使製造商設計出能夠最大限度減少有害產品差異、降低能源消耗並提供檢驗的監管鏈數據的產品。同時，數位化正在增強監控和檢驗。內建感測器和遠距離診斷能夠實現持續的效能評估和預測性維護，從而減少停機時間，並在更長的服務週期內保持產品的有效性。總而言之，這些轉變正在開啟一個新時代，在這個時代，多學科產品系列和以證據為導向的部署策略將成為實現競爭優勢和贏得公眾信任的基礎。

評估美國近期關稅調整如何重塑病毒惰性價值鏈的籌資策略、供應鏈韌性和供應商關係。

美國2025年實施的關稅和貿易政策調整對病毒惰性生態系統的供應鏈、籌資策略和供應商關係產生了連鎖反應。對於依賴進口組件（例如專用燈具、輻射源和某些化學前驅物）的機構而言，進口成本的增加促使他們更加關注供應鏈的韌性和總到岸成本。因此，採購團隊和技術負責人正在優先考慮供應商多元化、盡可能在地採購以及長期合約安排，以降低政策波動帶來的風險。

此外，這些貿易動態正在加速製造和組裝本地化舉措。企業正在評估關鍵設備和耗材的近岸外包方案，以縮短前置作業時間並加強品管。同時，研發計畫也進行了調整，更加重視替代化學方法和模組化設備架構，以便在不影響功能性能的前提下替換受影響的組件。最後，行業相關人員正在加強與監管機構和貿易當局的溝通，以明確分類、關稅待遇和合規要求，他們認知到，積極主動的政策對話可以減少營運不確定性，並維持關鍵病毒惰性能力的持續性。

從產品、方法、應用和最終用戶等維度進行詳細的細分分析，以指南病毒惰性的選擇、檢驗和部署策略。

了解這種細分對於制定病毒惰性產品選擇和部署策略至關重要。耗材包括化學試劑套件、消毒劑和紫外線燈，這些產品均針對常規應用或更換而配製或包裝。設備包括過濾系統、輻照平台和滅菌機，它們構成耐用的基礎設施，並需要不同的驗證和維護方案。這種細分會影響採購時機、操作人員培訓需求以及生命週期管理實務。

從方法來看，該領域可分為化學處理、熱處理和物理處理三大類。化學處理方法包括使用二氧化氯、環氧乙烷和過氧化氫等試劑，每種試劑都因其特定的有效性、材料相容性和可加工性而被選中。熱處理方法分為乾熱和濕熱兩種，可提供適用於不同基材的穿透深度和衝擊特性。物理處理方法包括電子束、伽馬射線和紫外線技術。紫外線處理方法又包括低壓汞燈和脈衝氙燈等子類型，這些子類型在頻譜輸出、能量效率以及對不同表面和氣流的適用性方面各不相同。

空氣淨化包括暖通空調系統和可攜式淨化器，旨在降低空氣中的病毒量。食品加工涵蓋飲料、乳製品和肉類加工，每種加工方式都有其獨特的衛生處理流程和監管限制。原料藥生產涵蓋活性生技藥品和疫苗的生產，其中無菌性和無菌保證至關重要。水處理涵蓋飲用水和污水處理，需要在有效控制副產物產生的同時，大幅降低病毒含量。最終使用者定義了操作要求和驗證的嚴格程度。生技公司（分為診斷和治療開發公司）要求可追溯性和通訊協定可重複性。食品和飲料加工商（涵蓋飲料、乳製品和肉類加工廠）優先考慮產量和殘留安全性。診所和醫院等醫療機構需要快速、安全且檢驗的惰性。實驗室，包括臨床和研究環境，需要靈活的方法來支援各種檢測和生物安全等級。

比較美洲、歐洲、中東和非洲以及亞太地區的區域動態和監管差異，這些差異會影響技術採納和採購選擇。

區域觀點影響病毒惰性的優先事項、監管環境和技術應用模式。在美洲，優先考慮營運擴充性、與現有基礎設施的整合以及遵守嚴格的公共衛生和職業安全標準，往往促使企業投資於能夠實現高通量和可預測檢驗結果的系統。因此，相關人員傾向於選擇兼具成熟有效性、高效運作和清晰合規路徑的解決方案。

監管協調和永續性要求是歐洲、中東和非洲的關鍵促進因素。在這些市場，政策制定者和機構投資者對環保化學品、節能設備和生命週期透明度表現出濃厚的興趣。該地區的許多組織正在採用能夠減少危險廢棄物並促進循環經濟實踐的技術，同時，採購決策也受到多方相關人員的審查。

在亞太地區，快速的工業擴張、多樣化的氣候條件以及監管成熟度的差異，既帶來了挑戰，也帶來了機會。市場採用的解決方案強調成本效益、對當地營運條件的適應性以及能夠在製造業和市政基礎設施中大規模部署的能力。區域製造商和整合商正透過創新來滿足對模組化系統和本地化支援網路的需求，而全球供應商則在建立夥伴關係和服務網路，以確保在不同司法管轄區都能應對力並符合相關規定。

整合的產品系列、策略夥伴關係和服務模式如何塑造競爭差異化，從而加速產品普及化並確保合規性？

病毒惰性領域的企業正透過技術深度、監管合規性和以服務為導向的產品組合脫穎而出。領先企業正投資於將耗材與相容設備結合的產品系列，從而提供捆綁式解決方案，簡化終端用戶的採購和檢驗。此外，隨著各組織尋求提供能夠減少採用障礙的承包解決方案，組件製造商、設備製造商和系統整合商之間的策略夥伴關係也變得越來越普遍。

研發管線專注於提升安全性、擴大對不同病毒家族的療效以及增強易用性。這促使企業加強與學術和臨床研究中心的合作，以進行獨立的績效檢驗和真實世界檢驗。同時，各公司也不斷完善市場推廣策略，提供延長保固期、遠端監控服務和培訓項目，以確保正確安裝和持續有效運作。合規方面的專業知識也是企業脫穎而出的關鍵。能夠駕馭複雜且競爭激烈的法規環境並提供完善檢驗文件的公司，更受製藥企業和醫療機構等高風險終端用戶的青睞。

產業領導者可採取切實可行的步驟，加強驗證實務、供應鏈韌性、監管參與和員工能力，以維持病毒惰性計畫。

產業領導者應優先採用以證據主導的綜合方法來維持產品的有效性、安全性和供應的連續性。首先，投資於模組化解決方案架構，以便在不改造整個系統的情況下更換組件，從而保持營運靈活性並簡化風險緩解措施。其次，建立跨職能驗證通訊協定，將實驗室有效性測試與現場性能監測相結合，以確保方法在實際應用條件下的穩健性。這樣做有助於企業降低變異性並增強相關人員的信心。

此外，企業必須將供應鏈韌性提升至策略要務。關鍵零件供應商應多元化，盡可能在本地進行生產和組裝，並納入合約保障措施以應對關稅和貿易風險。同時，應優先考慮能夠最大限度減少有害副產品和能源消耗的產品設計，以符合日益嚴格的法規和永續性預期。與監管機構合作並參與標準制定流程也有助於縮短核准時間，並明確遵守途徑。最後，企業應投資於培訓模組、數位化支援工具和能力評估，以提升員工能力，確保營運的穩定性和安全性，並在員工流動率不斷上升的情況下維護組織知識。

採用透明的混合方法研究途徑，整合一手訪談、二手文獻綜述和檢驗通訊協定，以確保獲得可靠且可操作的見解。

本報告的調查方法整合了多方面的證據，旨在提供可靠、可追溯的洞見，同時保持方法論的透明度。主要質性研究包括對臨床、工業和實驗室環境中的最終使用者進行結構化訪談，以及諮詢病毒學、材料科學和法規事務領域的專家。這些訪談旨在了解操作限制、驗證實務和採購優先事項，並在保密條件下進行，以獲得坦誠、務實的觀點。

二級研究系統地查閱了同行評審文獻、技術標準、監管指導文件和供應商技術規範，以確定技術特性和適用性的基礎。實驗室性能數據與獨立的檢驗研究進行交叉比對，以檢驗功效聲明並了解方法的局限性。數據綜合採用三角測量技術來協調不同資訊來源之間的差異，研究結果經過內部同儕審查和品質檢查。倫理考量，包括訪談資料的匿名化和潛在利益衝突的揭露，是確保分析可靠性和可重複性的方法論的重要組成部分。

檢驗綜合和策略重點，著重於可重複驗證、供應鏈適應性和永續設計

總之，病毒惰性已發展成為一個多學科交叉領域，技術創新、監管要求和實際操作情況相互交織，共同決定最終的成功。整合耗材和設備、採用混合方法並納入持續監測的整合策略正日益被公認為最佳實踐。隨著各組織機構應對不斷變化的政策環境和供應鏈壓力，其韌性將取決於能否在維持嚴格的安全性和有效性標準的同時，靈活調整採購、檢驗和部署模式。

展望未來，相關人員，將更有能力把技術進步轉化為可靠的營運績效。透過專注於可重複檢驗、供應鏈適應性和永續設計原則，實驗室可以確保其病毒惰性策略不僅滿足當前的營運需求，還能支持長期的公共衛生和商業連續性目標。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 疫情應對策略推動了UV-C LED消毒系統在醫療機構和公共交通樞紐的快速應用。
  • 向養老院和醫院引入自動化機器人表面消毒解決方案，以高效消除病毒
  • 消費者清潔產品市場對環保型和可生物分解的化學殺病毒配方的需求日益成長
  • 照護現場病毒惰性設備在臨床環境中的出現，旨在最大限度地降低交叉感染風險。
  • 關鍵市場病毒功效測試標準的監管協調統一將縮短產品核可時間。
  • 增加對奈米技術的投資，為公共場所高頻接觸表面提供抗病毒塗層，以減少感染傳播。
  • 開發一種基於物聯網的監測平台，用於即時追蹤工業環境中的病毒惰性過程
  • 採用動態療法和化學消毒劑結合的通訊協定來增強病毒抑制效果。

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 病毒惰性產品市場

  • 消耗品
    • 化學試劑套件
    • 消毒劑
    • 紫外線燈
  • 裝置
    • 過濾設備
    • 照射裝置
    • 消毒器

9. 依方法分類的病毒惰性市場

  • 化學處理
    • 二氧化氯
    • 環氧乙烷
    • 過氧化氫
  • 熱處理
    • 乾熱
    • 濕熱
  • 物理處理
    • 電子束
    • 伽瑪射線
    • 紫外線
      • 低壓汞
      • 脈衝氙氣

第10章 病毒惰性市場（依應用領域分類）

  • 空氣淨化
    • 暖通空調系統
    • 可攜式水質淨化器
  • 食品加工
    • 飲料加工
    • 乳製品加工
    • 肉類加工
  • 製藥生產
    • API生產
    • 生物製藥生產
    • 疫苗生產
  • 水處理
    • 飲用水處理
    • 污水處理

第11章 病毒惰性市場（依最終用戶分類）

  • 生技公司
    • 診斷開發人員
    • 治療藥物研發人員
  • 食品和飲料加工商
    • 飲料廠
    • 乳品廠
    • 肉類加工廠
  • 醫療機構
    • 診所
    • 醫院
  • 研究所
    • 臨床實驗室
    • 實驗室

第12章 病毒惰性市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 病毒惰性市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國病毒惰性市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Ecolab Inc.
    • STERIS Corporation
    • 3M Company
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Sartorius AG
    • Danaher Corporation
    • Lonza Group AG
    • Repligen Corporation
    • Novasep SAS
Product Code: MRR-034B5003039F

The Viral Inactivation Market is projected to grow by USD 3.43 billion at a CAGR of 15.04% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.11 billion
Estimated Year [2025] USD 1.28 billion
Forecast Year [2032] USD 3.43 billion
CAGR (%) 15.04%

Establishing the strategic and scientific context for viral inactivation to illuminate cross-sector drivers and why integrated solutions are pivotal for operational resilience

The viral inactivation domain has evolved into a technically sophisticated and cross-sectoral discipline, where science, regulatory frameworks, and operational requirements intersect to protect public health and commercial continuity. This introduction frames the critical themes that shape contemporary decision-making: technological convergence among chemical, physical, and thermal methods; heightened regulatory scrutiny across product classes; and a stronger emphasis on end-to-end validation from R&D through deployment. By establishing this context, stakeholders can better appreciate how innovations in consumables and equipment are being driven by practical needs in air, water, food, and pharmaceutical systems.

Moreover, the introduction underscores why integrated approaches are gaining favor. As organizations seek to deliver reproducible outcomes under varied environmental conditions, multidisciplinary strategies that pair consumables such as disinfectant solutions and chemical kits with specialized equipment become essential. At the same time, regulatory compliance and operator safety considerations are steering product design toward reduced toxicity, enhanced traceability, and simplified protocols. Therefore, this opening section situates viral inactivation not merely as a laboratory concern but as a strategic capability that underpins resilience across supply chains and critical services.

How emerging technologies, regulatory priorities, and operational demands are converging to reshape protocols and fuel integrated viral inactivation approaches

The landscape for viral inactivation is undergoing transformative shifts propelled by technological advances and evolving stakeholder expectations. New instrumentation and automation have increased throughput and consistency, while innovations in chemical formulations and UV sources have improved spectrum coverage and material compatibility. Consequently, practitioners are progressively moving away from single-method reliance toward hybrid protocols that combine chemical, thermal, and physical modalities to achieve robust inactivation across diverse matrices.

Regulatory and societal pressures are also reshaping adoption patterns. In addition to compliance with established standards, organizations now face demands for sustainability, worker safety, and demonstrable traceability. These dynamics are prompting manufacturers to design products that minimize hazardous byproducts, reduce energy intensity, and offer verifiable chain-of-custody data. Simultaneously, digitalization is enhancing monitoring and validation; embedded sensors and remote diagnostics allow continuous performance assessment and enable predictive maintenance, which reduces downtime and preserves efficacy over extended service cycles. Taken together, these shifts are driving a new era in which multidisciplinary product portfolios and evidence-centered deployment strategies are the basis for competitive differentiation and public confidence.

Assessing how recent United States tariff adjustments have reshaped procurement strategies, supply chain resilience, and supplier relationships across viral inactivation value chains

The introduction of tariffs and trade policy adjustments in the United States during 2025 has created ripple effects across supply chains, procurement strategies, and vendor relationships that touch the viral inactivation ecosystem. For organizations that rely on imported components such as specialized lamps, radiation sources, or certain chemical precursors, increased import costs have elevated attention on supply chain resilience and total landed cost. As a result, procurement teams and technical leaders have prioritized supplier diversification, local sourcing where feasible, and longer-term contractual arrangements to mitigate exposure to policy fluctuations.

Moreover, these trade dynamics have accelerated localization initiatives in manufacturing and assembly. Firms are evaluating nearshoring options for critical equipment and consumables to reduce lead times and strengthen quality control. In parallel, research and development planning has adapted by emphasizing alternative chemistries and modular equipment architectures that permit substitution of impacted components without compromising functional performance. Finally, industry stakeholders have intensified engagement with regulatory and trade authorities to clarify classification, duty treatment, and compliance requirements, recognizing that proactive policy dialogue can reduce operational uncertainty and maintain continuity of essential viral inactivation capabilities.

Detailed segmentation analysis across product, method, application, and end-user dimensions to guide selection, validation, and deployment strategies in viral inactivation

Understanding segmentation is essential to navigating product selection and deployment strategies in viral inactivation. When the market is examined by product, there is a clear bifurcation between consumables and equipment: consumables encompass chemical kits, disinfectant solutions, and UV lamps that are formulated or packaged for routine application and replacement, while equipment covers filtration systems, irradiation platforms, and sterilization machinery that provide durable infrastructure and require different validation and maintenance regimes. This division informs purchasing cadence, operational training needs, and lifecycle management practices.

In terms of method, the domain is shaped by chemical treatment, heat treatment, and physical treatment categories. Chemical approaches include agents such as chlorine dioxide, ethylene oxide, and hydrogen peroxide, each chosen for specific efficacy, material compatibility, and throughput considerations. Heat-based methods split into dry heat and moist heat options, delivering differing penetrative and material impact profiles suitable for varying substrates. Physical modalities involve electron beam, gamma radiation, and ultraviolet technologies; within ultraviolet approaches there are subtypes such as low pressure mercury and pulsed xenon sources, which differ in spectral output, energy efficiency, and applicability across surfaces and air volumes.

Application-driven segmentation further clarifies deployment contexts: air purification spans HVAC systems and portable purifiers designed to reduce airborne viral load; food processing encompasses beverage processing, dairy processing, and meat processing with unique sanitation cycles and regulatory constraints; pharmaceutical manufacturing includes active pharmaceutical ingredient production, biologics production, and vaccine production where sterility and aseptic assurance are paramount; water treatment addresses drinking water and wastewater treatment operations that require robust viral reduction while managing byproduct formation. Finally, end users define operational requirements and validation rigor: biotechnology firms-split between diagnostic developers and therapeutics developers-demand traceability and protocol reproducibility; food and beverage processors-across beverage, dairy, and meat plants-prioritize throughput and residual safety; healthcare facilities such as clinics and hospitals need rapid, safe, and verifiable inactivation; and laboratories, including clinical and research settings, require flexible methods that support a range of assays and containment levels.

Comparative regional dynamics and regulatory nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence technology adoption and procurement choices

Regional perspectives shape priorities, regulatory requirements, and technology adoption patterns across the viral inactivation landscape. In the Americas, emphasis tends to center on operational scalability, integration with existing infrastructure, and adherence to stringent public health and occupational safety standards; investments frequently target systems that enable high throughput and predictable validation outcomes. Consequently, stakeholders favor solutions that combine proven efficacy with operational efficiency and clear compliance pathways.

In Europe, Middle East & Africa, regulatory harmonization efforts and sustainability mandates are influential drivers. Across these markets, policymakers and institutional purchasers exhibit strong interest in environmentally responsible chemistries, energy-efficient equipment, and lifecycle transparency. Many organizations in this region are adopting technologies that reduce hazardous waste and enable circular economy practices, while procurement decisions are informed by multi-stakeholder scrutiny.

In the Asia-Pacific region, rapid industrial expansion, diverse climatic conditions, and varying regulatory maturity create both challenges and opportunities. Adoption patterns emphasize cost-effectiveness, adaptability to local operational contexts, and solutions that can be deployed at scale across manufacturing and municipal infrastructures. Regional manufacturers and integrators are innovating to meet demand for modular systems and localized support networks, while global suppliers are establishing partnerships and service footprints to ensure responsiveness and compliance across diverse jurisdictions.

How competitive differentiation is being shaped by integrated product portfolios, strategic partnerships, and service models that accelerate adoption and ensure regulatory compliance

Companies operating in the viral inactivation arena are differentiating through a mix of technological depth, regulatory alignment, and service-oriented offerings. Leaders are investing in product portfolios that blend consumables with compatible equipment, thereby enabling bundled solutions that simplify procurement and validation for end users. In addition, strategic partnerships between ingredient formulators, equipment manufacturers, and systems integrators are becoming more common as organizations look to offer turnkey solutions that reduce adoption friction.

Research and development pipelines are focused on improving safety profiles, expanding efficacy across viral families, and enhancing ease of use. This has prompted increased collaboration with academic and clinical research centers for independent performance verification and real-world validation. Meanwhile, companies are refining their go-to-market strategies by offering extended warranties, remote monitoring services, and training programs to ensure proper installation and sustained performance. Competitive differentiation also arises from compliance expertise; firms that can navigate complex regulatory environments and provide documented validation packages gain preferential consideration among high-stakes end users such as pharmaceutical manufacturers and healthcare institutions.

Actionable steps for industry leaders to strengthen validation practices, supply chain resilience, regulatory engagement, and workforce capability to sustain viral inactivation programs

Industry leaders should prioritize an integrated, evidence-driven approach to maintain efficacy, safety, and supply continuity. First, invest in modular solution architectures that allow substitution of components without requalifying entire systems, which preserves operational flexibility and simplifies risk mitigation. Second, establish cross-functional validation protocols that combine laboratory efficacy testing with field performance monitoring to ensure method resilience across real-world conditions. By doing so, organizations can reduce variability and strengthen stakeholder confidence.

Furthermore, supply chain resilience must be elevated to a strategic imperative. Diversify suppliers for critical components, pursue localized manufacturing or assembly where feasible, and include contractual safeguards that address tariff and trade risk. In parallel, prioritize product designs that minimize hazardous byproducts and energy consumption to align with tightening regulatory and sustainability expectations. Collaboration with regulatory bodies and participation in standards development processes will also pay dividends by reducing approval timelines and clarifying compliance pathways. Finally, invest in workforce capability building-training modules, digital support tools, and competency assessments-to ensure consistent, safe operation and to preserve institutional knowledge amid workforce turnover.

A transparent mixed-methods research approach integrating primary interviews, secondary literature synthesis, and validation protocols to ensure credible and actionable insights

The research methodology underpinning this report synthesizes multiple evidence streams to provide robust, traceable insights while maintaining methodological transparency. Primary qualitative engagement included structured interviews with end users across clinical, industrial, and laboratory settings, along with consultations with subject-matter experts in virology, materials science, and regulatory affairs. These interviews were designed to capture operational constraints, validation practices, and procurement priorities, and were conducted under confidentiality to elicit candid, practical perspectives.

Secondary research encompassed a systematic review of peer-reviewed literature, technical standards, regulatory guidance documents, and supplier technical specifications to establish an evidence base for technology characteristics and application fit. Laboratory performance data and independent validation studies were cross-referenced to verify efficacy claims and to understand method limitations. Data synthesis applied triangulation techniques to reconcile differences across sources, and findings were subject to internal peer review and quality checks. Ethical considerations, including anonymization of interview data and disclosure of potential conflicts of interest, were integral to the methodology to ensure credibility and reproducibility of the analysis.

Synthesis of evidence and strategic priorities that emphasize reproducible validation, supply chain adaptability, and sustainable design for enduring operational effectiveness

In conclusion, viral inactivation has matured into a multidisciplinary field where technical innovation, regulatory requirements, and operational realities coalesce to determine successful outcomes. Integrated strategies that combine consumables and equipment, leverage hybrid methodologies, and incorporate continuous monitoring are increasingly recognized as best practice. As organizations contend with evolving policy environments and supply chain pressures, resilience will hinge on the ability to adapt procurement, validation, and deployment models while maintaining rigorous safety and efficacy standards.

Looking ahead, stakeholders who prioritize evidence-backed product selection, proactive engagement with regulatory bodies, and investments in workforce capability will be best positioned to translate technological advances into dependable operational performance. By focusing on reproducible validation, supply chain adaptability, and sustainable design principles, institutions can ensure that viral inactivation strategies not only meet immediate operational needs but also support long-term public health and commercial continuity objectives.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of UV-C LED disinfection systems in healthcare and public transportation hubs driven by pandemic preparedness strategies
  • 5.2. Integration of automated robotic surface disinfection solutions in nursing homes and hospitals for efficient viral elimination
  • 5.3. Rising demand for green and biodegradable chemical virucidal formulations in consumer cleaning products markets
  • 5.4. Emergence of point of care viral inactivation devices in clinical settings to minimize cross contamination risks
  • 5.5. Regulatory alignment on viral efficacy testing standards across key markets improving product approval timelines
  • 5.6. Increased investment in nanotechnology enabled antiviral coatings for high touch public surfaces to reduce transmission
  • 5.7. Development of IoT enabled monitoring platforms for real time tracking of viral inactivation processes in industrial settings
  • 5.8. Adoption of combined photodynamic therapy and chemical disinfectant protocols to enhance viral suppression efficacy

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Viral Inactivation Market, by Product

  • 8.1. Consumables
    • 8.1.1. Chemical Kits
    • 8.1.2. Disinfectant Solutions
    • 8.1.3. Uv Lamps
  • 8.2. Equipment
    • 8.2.1. Filtration Equipment
    • 8.2.2. Irradiation Equipment
    • 8.2.3. Sterilization Equipment

9. Viral Inactivation Market, by Method

  • 9.1. Chemical Treatment
    • 9.1.1. Chlorine Dioxide
    • 9.1.2. Ethylene Oxide
    • 9.1.3. Hydrogen Peroxide
  • 9.2. Heat Treatment
    • 9.2.1. Dry Heat
    • 9.2.2. Moist Heat
  • 9.3. Physical Treatment
    • 9.3.1. Electron Beam
    • 9.3.2. Gamma Radiation
    • 9.3.3. Ultraviolet
      • 9.3.3.1. Low Pressure Mercury
      • 9.3.3.2. Pulsed Xenon

10. Viral Inactivation Market, by Application

  • 10.1. Air Purification
    • 10.1.1. Hvac Systems
    • 10.1.2. Portable Purifiers
  • 10.2. Food Processing
    • 10.2.1. Beverage Processing
    • 10.2.2. Dairy Processing
    • 10.2.3. Meat Processing
  • 10.3. Pharmaceutical Manufacturing
    • 10.3.1. API Production
    • 10.3.2. Biologics Production
    • 10.3.3. Vaccine Production
  • 10.4. Water Treatment
    • 10.4.1. Drinking Water Treatment
    • 10.4.2. Wastewater Treatment

11. Viral Inactivation Market, by End User

  • 11.1. Biotechnology Firms
    • 11.1.1. Diagnostic Developers
    • 11.1.2. Therapeutics Developers
  • 11.2. Food And Beverage Processors
    • 11.2.1. Beverage Plants
    • 11.2.2. Dairy Plants
    • 11.2.3. Meat Plants
  • 11.3. Healthcare Facilities
    • 11.3.1. Clinics
    • 11.3.2. Hospitals
  • 11.4. Laboratories
    • 11.4.1. Clinical Laboratories
    • 11.4.2. Research Laboratories

12. Viral Inactivation Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Viral Inactivation Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Viral Inactivation Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Ecolab Inc.
    • 15.3.2. STERIS Corporation
    • 15.3.3. 3M Company
    • 15.3.4. Thermo Fisher Scientific Inc.
    • 15.3.5. Merck KGaA
    • 15.3.6. Sartorius AG
    • 15.3.7. Danaher Corporation
    • 15.3.8. Lonza Group AG
    • 15.3.9. Repligen Corporation
    • 15.3.10. Novasep SAS

LIST OF FIGURES

  • FIGURE 1. GLOBAL VIRAL INACTIVATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS VIRAL INACTIVATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA VIRAL INACTIVATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. VIRAL INACTIVATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. VIRAL INACTIVATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VIRAL INACTIVATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VIRAL INACTIVATION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VIRAL INACTIVATION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DISINFECTANT SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DISINFECTANT SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DISINFECTANT SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DISINFECTANT SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DISINFECTANT SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DISINFECTANT SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY UV LAMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY UV LAMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY UV LAMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY UV LAMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY UV LAMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY UV LAMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FILTRATION EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FILTRATION EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FILTRATION EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FILTRATION EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FILTRATION EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FILTRATION EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY IRRADIATION EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY IRRADIATION EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY IRRADIATION EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY IRRADIATION EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY IRRADIATION EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY IRRADIATION EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY STERILIZATION EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY STERILIZATION EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY STERILIZATION EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY STERILIZATION EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY STERILIZATION EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY STERILIZATION EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHEMICAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHLORINE DIOXIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHLORINE DIOXIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHLORINE DIOXIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHLORINE DIOXIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHLORINE DIOXIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CHLORINE DIOXIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ETHYLENE OXIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ETHYLENE OXIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ETHYLENE OXIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ETHYLENE OXIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ETHYLENE OXIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ETHYLENE OXIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HYDROGEN PEROXIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HYDROGEN PEROXIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HYDROGEN PEROXIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HYDROGEN PEROXIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HYDROGEN PEROXIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HYDROGEN PEROXIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEAT TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DRY HEAT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DRY HEAT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DRY HEAT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DRY HEAT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DRY HEAT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DRY HEAT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MOIST HEAT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MOIST HEAT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MOIST HEAT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MOIST HEAT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MOIST HEAT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MOIST HEAT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHYSICAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ELECTRON BEAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ELECTRON BEAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ELECTRON BEAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ELECTRON BEAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ELECTRON BEAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ELECTRON BEAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY GAMMA RADIATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY GAMMA RADIATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY GAMMA RADIATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY GAMMA RADIATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY GAMMA RADIATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY GAMMA RADIATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ULTRAVIOLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LOW PRESSURE MERCURY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LOW PRESSURE MERCURY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LOW PRESSURE MERCURY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LOW PRESSURE MERCURY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LOW PRESSURE MERCURY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LOW PRESSURE MERCURY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PULSED XENON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PULSED XENON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PULSED XENON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PULSED XENON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PULSED XENON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PULSED XENON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY AIR PURIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HVAC SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HVAC SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HVAC SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HVAC SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HVAC SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HVAC SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PORTABLE PURIFIERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PORTABLE PURIFIERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PORTABLE PURIFIERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PORTABLE PURIFIERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PORTABLE PURIFIERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PORTABLE PURIFIERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD PROCESSING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BEVERAGE PROCESSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BEVERAGE PROCESSING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BEVERAGE PROCESSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BEVERAGE PROCESSING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BEVERAGE PROCESSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BEVERAGE PROCESSING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DAIRY PROCESSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DAIRY PROCESSING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DAIRY PROCESSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DAIRY PROCESSING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DAIRY PROCESSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DAIRY PROCESSING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MEAT PROCESSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MEAT PROCESSING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MEAT PROCESSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MEAT PROCESSING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MEAT PROCESSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MEAT PROCESSING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY API PRODUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY API PRODUCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY API PRODUCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY API PRODUCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY API PRODUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY API PRODUCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOLOGICS PRODUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOLOGICS PRODUCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOLOGICS PRODUCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOLOGICS PRODUCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOLOGICS PRODUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOLOGICS PRODUCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY VACCINE PRODUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY VACCINE PRODUCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY VACCINE PRODUCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY VACCINE PRODUCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY VACCINE PRODUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY VACCINE PRODUCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WATER TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DRINKING WATER TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DRINKING WATER TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DRINKING WATER TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DRINKING WATER TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DRINKING WATER TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DRINKING WATER TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WASTEWATER TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WASTEWATER TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WASTEWATER TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WASTEWATER TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WASTEWATER TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY WASTEWATER TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DIAGNOSTIC DEVELOPERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DIAGNOSTIC DEVELOPERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DIAGNOSTIC DEVELOPERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DIAGNOSTIC DEVELOPERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DIAGNOSTIC DEVELOPERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DIAGNOSTIC DEVELOPERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY THERAPEUTICS DEVELOPERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY THERAPEUTICS DEVELOPERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY THERAPEUTICS DEVELOPERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY THERAPEUTICS DEVELOPERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY THERAPEUTICS DEVELOPERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY THERAPEUTICS DEVELOPERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY FOOD AND BEVERAGE PROCESSORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BEVERAGE PLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BEVERAGE PLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BEVERAGE PLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BEVERAGE PLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BEVERAGE PLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BEVERAGE PLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DAIRY PLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DAIRY PLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DAIRY PLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DAIRY PLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DAIRY PLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY DAIRY PLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MEAT PLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MEAT PLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MEAT PLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MEAT PLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MEAT PLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY MEAT PLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HEALTHCARE FACILITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 315. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 316. GLOBAL VIRAL INACTIVATION MARKET SI